{"id":"dzp","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Sedation/drowsiness"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Ataxia/coordination impairment"},{"rate":null,"effect":"Dependence/withdrawal risk"},{"rate":"5-10","effect":"Cognitive impairment"}]},"_chembl":{"chemblId":"CHEMBL12","moleculeType":"Small molecule","molecularWeight":"284.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benzodiazepines like DZP bind allosterically to GABA-A receptors and increase the frequency of chloride channel opening, leading to hyperpolarization of neurons and reduced neuronal excitability. This results in anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. The drug is commonly used for anxiety disorders, seizure management, and acute alcohol withdrawal.","oneSentence":"DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:08.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Seizure disorders"},{"name":"Acute alcohol withdrawal"},{"name":"Muscle spasticity"}]},"trialDetails":[{"nctId":"NCT04976322","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2021-07-27","conditions":"Systemic Lupus Erythematosus","enrollment":760},{"nctId":"NCT06617325","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-11-21","conditions":"Systemic Lupus Erythematosus","enrollment":450},{"nctId":"NCT04294667","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-08-12","conditions":"Systemic Lupus Erythematosus","enrollment":321},{"nctId":"NCT04571424","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-10-14","conditions":"Healthy Volunteers","enrollment":33},{"nctId":"NCT02804763","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2016-06-02","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":722,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CDP7657"],"phase":"phase_3","status":"active","brandName":"DZP","genericName":"DZP","companyName":"UCB Biopharma SRL","companyId":"ucb-biopharma-srl","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system. Used for Anxiety disorders, Seizure disorders, Acute alcohol withdrawal.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}